FDA Approves SEGLUROMET — Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC received FDA approval on Dec. 19, 2017, for Segluromet, a fixed-dose tablet containing ertugliflozin and metformin, which is poised to bolster the company's portfolio of type 2 diabetes therapeutics. This approval expands the market for ertugliflozin pidolate based on the demonstrated efficacy of its components and capitalizes on the growing demand for combination therapies in the diabetes sector.